Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

1.

Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy.

Pouilles JM, Tremollieres F, Roux C, Sebert JL, Alexandre C, Goldberg D, Treves R, Khalifa P, Duntze P, Horlait S, Delmas P, Kuntz D.

Osteoporos Int. 1997;7(3):213-8.

PMID:
9205633
[PubMed - indexed for MEDLINE]
2.
3.

Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.

Fogelman I, Herd RJ, Blake GM, Balena R.

Calcif Tissue Int. 2000 May;66(5):348-54.

PMID:
10773104
[PubMed - indexed for MEDLINE]
5.

The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.

Chaki O, Yoshikata I, Kikuchi R, Nakayama M, Uchiyama Y, Hirahara F, Gorai I.

J Bone Miner Res. 2000 Aug;15(8):1537-44.

PMID:
10934652
[PubMed - indexed for MEDLINE]
6.

Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist.

Zamberlan N, Castello R, Gatti D, Rossini M, Braga V, Fracassi E, Adami S.

Osteoporos Int. 1997;7(2):133-7.

PMID:
9166393
[PubMed - indexed for MEDLINE]
7.
8.

Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.

Heikkinen JE, Selander KS, Laitinen K, Arnala I, Väänänen HK.

J Bone Miner Res. 1997 Jan;12(1):103-10.

PMID:
9240732
[PubMed - indexed for MEDLINE]
9.

The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study.

Herd RJ, Balena R, Blake GM, Ryan PJ, Fogelman I.

Am J Med. 1997 Aug;103(2):92-9.

PMID:
9274891
[PubMed - indexed for MEDLINE]
10.

Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis.

Iwamoto J, Takeda T, Ichimura S, Uzawa M.

Keio J Med. 2003 Jun;52(2):113-9.

PMID:
12862363
[PubMed - indexed for MEDLINE]
Free Article
11.

Matrix delivery transdermal 17beta-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group.

Cooper C, Stakkestad JA, Radowicki S, Hardy P, Pilate C, Dain MP, Delmas PD.

Osteoporos Int. 1999;9(4):358-66.

PMID:
10550454
[PubMed - indexed for MEDLINE]
12.

A 3-year study of prevention of postmenopausal bone loss: conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone.

Thiébaud D, Bigler JM, Renteria S, Pache T, Welti HJ, Landry M, Burckhardt P.

Climacteric. 1998 Sep;1(3):202-10.

PMID:
11907945
[PubMed - indexed for MEDLINE]
13.

Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.

Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut CH 3rd.

Am J Med. 1997 Dec;103(6):468-76. Erratum in: m J Med 1998 Jun;104(6):608.

PMID:
9428829
[PubMed - indexed for MEDLINE]
14.

Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.

Stakkestad JA, Benevolenskaya LI, Stepan JJ, Skag A, Nordby A, Oefjord E, Burdeska A, Jonkanski I, Mahoney P; Ibandronate Intravenous Study Group.

Ann Rheum Dis. 2003 Oct;62(10):969-75.

PMID:
12972476
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
[PubMed - indexed for MEDLINE]
16.

Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy.

Fujita T, Satomura A, Hidaka M, Ohsawa I, Endo M, Ohi H.

Calcif Tissue Int. 2000 Mar;66(3):195-9.

PMID:
10666494
[PubMed - indexed for MEDLINE]
17.
18.

Prevention of early postmenopausal bone loss with cyclical etidronate.

Adami S, Bruni V, Bianchini D, Becorpi A, Lombardi P, Campagnoli C, Ferrari A, Marchesoni T, Balena R.

J Endocrinol Invest. 2000 May;23(5):310-6.

PMID:
10882149
[PubMed - indexed for MEDLINE]
19.

Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women.

Tseng LN, Sheu WH, Ho ES, Lan HH, Hu CC, Kao CH.

Metabolism. 2006 Jun;55(6):741-7.

PMID:
16713432
[PubMed - indexed for MEDLINE]
20.

A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.

Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H; Risedronate Phase III Research Group.

Osteoporos Int. 2002 Dec;13(12):971-9.

PMID:
12459940
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk